2017 American Transplant Congress
Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers.
Background:Direct-acting antivirals (DAAs) have been shown to have high cure rates in hepatitis C (HCV)-positive liver transplantation (LT) recipients. The organ donor shortage has led…2017 American Transplant Congress
Evaluation of Low Dose Valganciclovir for the Prevention of Cytomegalovirus in Liver Transplant Recipients.
BACKGROUND: Cytomegalovirus (CMV) causes significant morbidity and mortality following orthotopic liver transplantation (OLT). Valganciclovir (VGCV) is used to prevent CMV, but at labeled doses can…2017 American Transplant Congress
Impact of Ritonavir on Graft Function in Human Immunodeficiency Virus Infected Kidney Transplant Recipients.
Emory University Hospital, Atlanta, GA
Purpose: The purpose of this study was to determine the difference in 6 and 12 month graft function between patients with human immunodeficiency virus (HIV)…2017 American Transplant Congress
Tenofovir Use Is Not Associated with Reduced Bone Density or Fractures in Liver Transplant Recipients.
University of Minnesota, Minneapolis, MN
BackgroundTenofovir disproxil fumarate (TDF) and reduced bone density in the HIV population is well-documented. The effect of TDF use on bone density in patients who…2017 American Transplant Congress
Influenza Viral Dynamics in a Large Cohort of Transplant Patients with Natural Influenza Infection.
Background:Influenza infection significantly impacts transplant patients. Despite this, there are limited data on how virological characteristics, including influenza viral load (VL), impact the outcome of…2017 American Transplant Congress
A Single Center's Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving an HCV Positive Kidney.
Background: Nearly 8% of patients in the U.S. undergoing hemodialysis are Hepatitis C (HCV) positive. There is a survival benefit in HCV positive patients who…2017 American Transplant Congress
Mutations in Influenza A Virus and Clinical Implications in Transplant Recipients.
1UHN, Toronto, Canada; 2REIPI, Seville, Spain; 3UPenn, Philadelphia; 4LUMC, Leiden, Netherlands
Background: Organ and hematopoietic stem cell transplant (HSCT) recipients are predisposed to complications of influenza infection and as such may constitute an important source of…2016 American Transplant Congress
Incidence of Viral Infections in HLA-Sensitized Patients (HS Pts) Desensitized with IVIG + Rituximab (DES) Compared to Non-HS Pts Receiving Standard Immunosuppression.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: HS pts (PRA>50%, DSA+ at transplant) who are transplanted without DES represent a significant risk for antibody-mediated rejection. Prior to transplantation, HS pts require…2016 American Transplant Congress
Characterization of Resistant Cytomegalovirus in Lung Transplant Recipients in the Modern Era.
NewYork-Presbyterian Hospital, New York, NY.
Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in lung transplant recipients (LTR) and the emergence of resistant CMV (rCMV) has increased. The…2016 American Transplant Congress
EBV Sero-Positivity Does Not Reduce the Risk for EBV Viremia and/or Post-Transplant Lymphoproliferative Disorder (PTLD) in Patients (Pts) Receiving Belatacept (CTLA4Ig).
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: CTLA4Ig is a novel immunosuppressive (IS) which acts through costimulatory blockade of T-cells and obviates the need for calcineurin inhibitor-based IS (CNI-IS). Despite benefits…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- 14
- Next Page »